Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...

The first FDA-approved systemic therapy may be beneficial to patients with low-grade astrocytoma or oligodendroglioma with IDH1 or 2 mutations. The recent Food and Drug Administration (FDA) approval ...

Factors associated with survival of central nervous system tumors in a population-based cancer registry. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

This can be used to predict patient prognosis and drive the development of novel therapies." Until a cure is found for the most aggressive astrocytomas, the priority for oncologists is to detect their ...

Pilocytic astrocytoma is a generally benign glial neoplasm classified as WHO grade I, most frequently encountered in children and young adults. These tumours exhibit a biphasic histological pattern, ...

A research team has discovered a previously overlooked subtype of brain tumor termed IME IDH-mutant astrocytoma. Contrary to typical medical expectations, this subtype exhibits strong immune activity, ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...

Irene Rodríguez-Hernández; Marta Vázquez-Cedeira; Angel Santos-Briz; Juan L García; Isabel F Fernández; Juan A Gómez-Moreta; Javier Martin-Vallejo; Rogelio González-Sarmiento; Pedro A Lazo In summary, ...